NPLB helps patient advocates, innovators, and investors be heard in Washington, DC.
NPLB's December letter mobilized hundreds of supporters to urge action on the "Build Back Better" (BBB) legislation so that it improves patient Rx affordability and ensures continued innovation. It requests policymakers lower the proposed Part D catastrophic cap to $1200 and eliminate its deductible altogether. The letter also recommends that BBB not deprioritize small-molecule investment in favor of costlier large-molecule biologics.
NPLB's September letter was cited by influential legislators as reason to make significant changes to the original Rx price control legislation HR 3.
NPLB continues to seek changes to BBB with the hope it can support both its passage and successful implementation.
April 8, 2023 - 400+ biotech and pharma executives voice support for the FDA's indispensable role in regulating new medicines. The letter warns that judicial orders undermining the decisions of the FDA would destroy the basic infrastructure necessary for continued medical innovation.
July 25, 2022 - 1000+ Investors, researchers, patients, & innovators urge critical fixes to Senate Rx Bill that can lower Medicare Rx deductibles, give the government greater power to set prices, and make sure biopharma research and development remains vigorous for both drugs and biologics.
December 14, 2021 - Biopharma patient advocates, innovators, and investors continue to urge Congress to fix the proposed Build Back Better (BBB) legislation to improve patient Rx affordability and preserve biopharma innovation.
September 8, 2021 - Pass reforms to lower out-of-pocket costs. Price controls could cease biopharma investment and prevent future cures.
Feel free to reach out with questions, concerns, or comments.
Contact us
